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Abstract
Rationale and objective Hypericum perforatum (St John's
wort) is used to treat depression, but the effectiveness has
not been established. Recent guidelines described the analysis
of clinical trials with missing data, inspiring the reanalysis of
this trial using proper missing data methods. The objective
was to determine whether hypericum was superior to placebo
in treating major depression.
Methods A placebo-controlled, randomized clinical trial was
conducted for 8 weeks to determine the effectiveness of
hypericum or sertraline in reducing depression, measured
using the Hamilton depression scale.We performed sensitivity
analyses under different assumptions about the missing data
process.
Results Three hundred forty participants were randomized,
with 28 % lost to follow-up. The missing data mechanism
was not missing completely at random. Under missing at
random assumptions, some sensitivity analyses found no dif-
ference between either treatment arm and placebo, while some
sensitivity analyses found a significant difference from base-
line to week 8 between sertraline and placebo (−1.28, 95 %
credible interval [−2.48; −0.08]), but not between hypericum
and placebo (0.56, [−0.64;1.76]). The results were similar
when the missing data process was assumed to be missing
not at random.
Conclusions There is no difference between hypericum and
placebo, regardless of the assumption about the missing data
process. There is a significant difference between sertraline
and placebo with some statistical methods used. It is important
to conduct an analysis that takes account of missing data using
valid statistically principled methods. The assumptions about
the missing data process could influence the results.
Keywords St John's wort .Hypericum perforatum . Herbal
medicine . Antidepressant . Sertraline . Hamilton depression
scale . Bayesian .Multiple imputation .Missing at random .
Missing not at random
Introduction
Hypericum perforatum
H . perforatum (St John's wort), is a herbal remedy used in the
treatment of depression, especially in European countries
(Fegert et al. 2006). It was shown to be more effective than
placebo (Kalb et al. 2001) in treating depression and is be-
lieved to have fewer side effects than standard antidepressive
therapies (Kasper et al. 2010; Linde et al. 1996). Some studies
and meta-analyses have found hypericum to be as effective as
standard antidepressive therapies (Linde et al. 2008; Rahimi
et al. 2009), while other studies found no difference between
hypericum and placebo (Shelton et al. 2001). Because differ-
ent studies had contradictory results about the effectiveness of
hypericum compared to placebo and standard antidepressive
drugs, a trial was designed to compare both a standard
antidepressive therapy (sertraline) and hypericum to placebo
(Hypericum Depression Trial Study Group 2002). Sertraline
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(trademark Zoloft) is an antidepressant of the selective sero-
tonin reuptake inhibitor (SSRI) class. The practicing clinician
will be interested in these results, since herbal preparations
should be used only when evidence exist that it is efficacious.
Missing data
Missing data are common in longitudinal clinical trials. Over
the last 30 years, methods were designed for the proper
analysis of clinical trial data when missing data are present.
This is summarized in two guidance documents by the
European Medicines agency, “Guideline on Missing Data in
Confirmatory Clinical Trials”(CHMP 2010), and the National
Research Council in the United States of America, “The
Prevention and Treatment of Missing Data in Clinical
Trials”(National Research Council 2010). The second report
was recently summarized in the New England Journal of
Medicine (NEJM) (Little et al. 2012). In the same issue, the
journal announced new review policies regarding missing
data (Ware et al. 2012). Reviewers will in future look at
aspects of trial design that reduce the impact of missing
data. Weighting or model-based methods will be preferred
over complete case analysis or single imputation methods.
The NEJMwill in future also require sensitivity analysis when
missing data are extensive.
Rubin (1976) described three different missing data mech-
anisms based on the level of dependence between the missing
data process and the measurement process. These are missing
completely at random, missing at random, and missing not at
random. Data are missing completely at random when the
probability of dropout is independent of both observed and
unobserved data, for example, when a sample was lost in the
laboratory or a patient did not attend a visit due to transport
problems. Data are missing at random when the reason for
dropout is known and associated with trial-related events
(Carpenter et al. 2002). The reason for dropout can depend
on observed data, but not on unobserved data, for example,
when a participant who is doing poorly is subsequently
discontinued from the trial by the clinician or as per partici-
pant's choice and a poor efficacy outcome is recorded in the
study database. When neither missing completely at random
nor missing at random is valid, data are missing not at random.
In this instance, the missingness can be explained by unob-
served outcomes, for example, when a participant whose
condition worsens stops coming to the clinic, and this wors-
ened condition is not observed. The missing data mechanism
cannot be determined using the data observed, except possibly
to confirm that the missing data mechanism is not missing
completely at random.
Ten years ago, it was standard practice to analyze clinical
trials using complete case analysis or single imputation tech-
niques including last observation carried forward (LOCF).
This is changing in favor of more appropriate methods and
recommendations now advise against these (Carpenter et al.
2004; Carpenter et al. 2013; CHMP 2010; Mallinckrodt et al.
2001; Molenberghs and Kenward 2007; Molenberghs et al.
2004; National Research Council 2010; Ratitch et al. 2013). In
2002, the hypericum clinical trial was published using
complete case analysis and last observation carried forward
(Hypericum Depression Trial Study Group 2002). In this
paper, we reanalyzed the data up to week 8, using princi-
pled methods suggested by current guidelines, which did
not exist in 2002. We use this trial as an example of the
changes in analyses that are required if the new guidelines
are to be adopted.
Materials and methods
Trial design
The trial was a randomized, double-blind, parallel-arm, 8-week
outpatient trial of hypericum, sertraline, or placebo treatment
for major depressive disorder, followed by 18 weeks of double-
blind continuation treatment in participants meeting response
criteria at week 8. The study consisted of an acute phase (the
first 8 weeks) and an optional continuation phase (fromweeks 8
to 26). The focus of this paper is on the acute phase only. The
specific inclusion and exclusion criteria are given in the trial
publication (Hypericum Depression Trial Study Group 2002).
The eligibility of participants was assessed, after which they
gave written informed consent and participated in a 1-week
placebo run-in. Participants meeting eligibility criteria after the
run-in were randomized to one of the three treatment arms in a
1:1:1 ratio. Participants were assessed weekly from week 1 to
week 8. The Hamilton depression scale (HAM-D) (Hamilton
1960), global assessment of functioning (GAF) scale, Clinical
Global impressions scale for severity (CGI-S) and improve-
ment (CGI-I), and the Beck Depression Inventory (BDI) were
assessed at all visits. Other safety-related information was also
collected, such as vital signs, adverse events, and blood chem-
istry and hematology (Hypericum Depression Trial Study
Group 2002). We analyze the response over time on HAM-D,
which is a measure of depression, with a higher score indicative
of more severe depression.
The primary hypothesis was whether hypericum is superior
to placebo after 8 weeks. The endpoint was defined as the
change in the HAM-D score from baseline to week 8. The
principal comparison was between the hypericum and placebo
arms. The sertraline arm was included as an active control arm
to validate the study, but no comparison between hypericum
and sertraline was intended and the trial was not powered for
such a comparison or for multiple comparisons with placebo
(Hypericum Depression Trial Study Group 2002). Details
about the proportion of patients discontinued, timing of dis-
continuation, and reason for discontinuation are provided.
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Statistical methods
In the original analysis, treatment differences in the change in
HAM-D total score from baseline to week 8 were evaluated
through a random coefficient regression model. Available
longitudinal scores through week 8 were modelled as a linear
function of fixed effects for treatment, site, sex, week, and
treatment by week, with random intercept and slope for each
patient. A secondary analysis was restricted to participants
who completed the acute phase (completer analysis), and
analysis of covariance models used last observation carried
forward; although these results were not given in the paper
(HypericumDepression Trial Study Group 2002). An analysis
of the data in the continuation phase was also done in a
separate paper. In this analysis, the HAM-D scores for com-
pleters at the final time point were compared and last obser-
vation carried forward was applied (Sarris et al. 2012). While
the random coefficient regression model could be appropriate
if the missing data mechanism is missing completely at ran-
dom or missing at random, last observation carried forward is
not an appropriate way of handling missing data, because it
might inflate the Type I error and create bias in the estimation
of mean change from baseline while producing standard errors
that are too small (Mallinckrodt et al. 2001). The random
coefficient regression model takes into account the expecta-
tion of the missing measurements, given the observed mea-
surements and is valid and unbiased under missing at random
(Molenberghs and Kenward 2007). It can be thought of as
aiming to estimate the treatment effect that would have been
observed if all participants had continued on treatment for the
full study duration (CHMP 2010).
We reanalyzed the data using principled missing data tech-
niques. Assumptions were made about the missing data mech-
anism and a series of sensitivity analyses were done under
these assumptions. If the missing data mechanism is miss-
ing completely at random, an available case or complete
case analysis would be valid, although this analysis would
have reduced power because of the exclusion of some
participants. If one assumes the missing data mechanism
is missing at random, several methods would be valid,
including maximum likelihood models, multiple imputa-
tion, and Bayesian analysis.
Likelihood-based approaches use a parametric model to
formulate a statistical model for the missing data and base
inferences on the likelihood function of the incomplete data.
The objective is to draw inference about a parameter, θ , in a
model f (y |θ ) for the response data that is not fully ob-
served. Under the missing at random assumption, θ and the
missing data model are functionally independent and miss-
ing data can be treated as ignorable. In this case, inference is
drawn about θ without having to specify a model that
relates the missing data process to the observed data
(National Research Council 2010).
In the absence of missing data, likelihood-based methods
entail the maximization of the full data likelihood. With in-
completeness, this likelihood is replaced by the observed data
likelihood, where the individual likelihoods are integrated
over the missing values, ∏
i¼1
N
∫ f yobsi ; ymissi ; rijθ;ψ
 
dymissi ;
where y indicate the outcome variable, r is the missing data
indicator, θ and ψ are parameter vectors describing the mea-
surement and missingness processes, respectively, and N is
the number of participants. Under ignorability and missing
completely at random or missing at random missingness, the
integral can be rewritten as an integral over the missing values
and the distribution of the missing data mechanism (under a














. We fitted a model
with fixed and random effects, including treatment, week, and
the interaction between treatment and week, adjusted for
repeated measures.
Single imputation has several limitations. When analyzing
observed data, it is assumed that measurements are made with
error. To assume that if data are missing, we can impute the
missing value without error (a single value) is unrealistic.
With conditional mean imputation, the imputed data are much
less variable than the observed data would have been. Thus,
analyzing imputed data as observed data leads to an underes-
timation of standard errors, p values, and confidence intervals
(Carpenter and Kenward 2007; CHMP 2010).
Multiple imputation, first suggested by Rubin (1976), over-
comes the limitations of single imputation. Multiple imputation
is done in three steps. In step 1, plausible values for missing
observations are imputed that reflect uncertainty about the miss-
ing data models, generally assuming the missing data process is
missing at random. These values are used to fill in or impute the
missing values. This process is repeated, resulting in the creation
of several complete data sets, taking into account the uncertainty
in estimating both the relationship between the variables and the
residual variability. These provide a representation of the distri-
bution of the missing data given the observed. In step 2, each of
these data sets is analyzed using complete data methods that
would have been appropriate had there been no missing data. In
Step 3 the results are combined, taking the uncertainty regarding
the imputations into account (Rubin 1976). This additional step
is needed to correctly estimate the variability of quantities
estimated from a completed data set. These results are unbiased
and have approximately the correct standard error (Horton and
Kleinman 2007; Molenberghs and Kenward 2007).
Multiple imputation is said to be proper if it leads to
consistent asymptotically normal estimators, correct variance
estimators, and valid tests. Generally, the imputation will be
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proper if all sources of variability and uncertainty are included
in the imputation model, including prediction errors of the
individual values and errors of estimation in the fitted coeffi-
cients of the imputation model (White et al. 2011). Multiple
imputation is done using Bayesian predictive distribution
and Monte Carlo Markov Chain sampling to generate the
imputation, assuming that the data follows a multivariate
normal distribution. The model used for imputation should
include all the variables included in the analysis model (to
ensure proper imputation), and all variables that could
improve the prediction.
Multiple imputation with 100 imputations was used to
analyze the change from baseline to week 8. The imputation
model included all observed values of HAM-D, age, sex, race,
duration of depression, BDI, CGI-S, CGI-I, and GAF scale at
baseline. The variables were selected because they were
believed to be factors that could predict HAM-D scores or
were included in the analysis model. The imputed datasets
were used to get the estimates of the change from baseline
to week 8, and the appropriate p values and summary
statistics were calculated using Rubin's rule (Rubin 1976).
The imputed datasets were also analyzed with a mixed
model as described previously.
At its core, multiple imputation uses Bayesian techniques,
since the imputations are sampled from a Bayesian posterior
distribution. Fully Bayesian approaches, where multiple
datasets are not imputed, are appropriate for the analysis of
missing data by specifying priors on all the parameters and
specifying distributions for the missing covariates (Daniels
and Hogan 2008; Horton and Kleinman 2007). The missing
data are then sampled from their conditional distribution via
the Gibbs sampler, an algorithm that samples a Markov
chain where the kernel is the product of the sequentially
updated full conditional distributions of the parameters and
the stationary distribution is the posterior distribution
(Geman and Geman 1984).
In Bayesian analyses, parameters are treated as random
variables. Probability statements are made about the model
parameters and not about the data. Bayesian analysis has three
components. The prior distribution, p (θ), reflects the distri-
bution of the parameters before the data are seen. The likeli-
hood, L (θ |D), gives the distribution of the observed data. The
posterior distribution uses Bayes' theorem to combine infor-
mation from the prior distribution and the likelihood and
expresses uncertainty about the unknown parameters after
seeing the data. In ignorable methods, the posterior distribu-
tion is p (θ |D )∝p (θ )L (θ |D). The Bayesian inference is done
by specifying a model, specifying prior distributions for the
parameters of the model, and then updating the prior informa-
tion on the parameters using the model specified and the data
observed to obtain the posterior distribution of the parameters.
In addition to specifying a missingness model, assumptions
about the missing data and the uncertainty around the missing
data can be made explicit through the prior distributions
(Daniels and Hogan 2008). The priors can be used to encode
information about the missing data process. Bayesianmethods
are a natural way of handling missing data because a proba-
bility distribution is estimated for each missing value,
allowing for uncertainty to be captured. Missing data are
treated as additional unknown quantities, thus, no distinc-
tion is made between missing data and unknown param-
eters. After specifying an appropriate joint model for the
observed and missing data and the model parameters, poste-
rior samples of the model parameters and missing values will
be generated using Markov Chain Monte Carlo methods
(Mason et al. 2012).
Letting Yij be the HAM-D score for participant i at occa-
sion j , where Yij~Normal(μ ij,σ
2), the following Bayesian
model was fitted:
μij ¼ β0 þ β1tij þ β2Si þ β3Hi þ β4Si þ β5Hið Þtij
where, t ij indicates occasion j (weekj) for participant i . Si is an
indicator variable for the sertraline arm and equals 1 if partic-
ipant i belongs to the sertraline arm and is 0 otherwise.
Similarly, Hi is an indicator variable for the hypericum arm
and equals 1 if participant i belongs to the hypericum arm and
is 0 otherwise. A participant i belonging to the placebo arm
will thus have Hi=Si=0. The placebo arm is therefore the
reference group. We assume N independent participants.
Vague priors were specified for the unknown parameters and
are given in Table 4. Sensitivity analyses were performed with
various prior distributions, to assess the sensitivity of the
Bayesianmodels to the choice of prior distribution. Priors could
also have been used to include data about the missingness
process. One could potentially use different prior distributions
for each of the treatment arms, if the prior beliefs about the
missingness mechanism warranted this.
Under missing not at random, an assumption we cannot test
using the observed data, Bayesian analyses, pattern mixture
models, selection models, and shared parameter models can
be used, at the expense of increased complexity.
Under a missing not at random assumption, we fitted three
Bayesian models under several different assumptions about
the missing data mechanism. Bayesian analysis provides a
flexible way to model missing not at random data, using a
selection model factorization of a joint model, consisting of a
model of interest and a model of missingness. The same
model for the observed data was fitted as under missing
at random and a model of missingness of the form
mij~Bernoulli(p ij), logit(p ij)=θ0+Δy ij was added, where
i =1,…, 340 indicates the participant and j =1, …8 indicates
the visit, mij is a binary missing value indicator for y ij. This
model allows the missingness to depend on the value that
would have been observed.
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A second missing not at random model was fitted
where the model of missingness had the following form:
logit pi,w=θ0+θ1yi,w−1+θ2( yi,w−yi,w−1). This model allows
the missingness to depend on the value that would have been
observed at the current occasion, where the value is possibly
missing, as well as on the previous observed value. In so doing,
in line with what is oftentimes done in a selection model
specification, missingness can be seen to depend on both the
level of the outcome (represented by the average of the current
and previous values) and the increment between the previous
and current values. It should be noted that the data do not carry
information on θ2 in the usual sense. While under a likelihood
and Bayesian paradigm parameters may be identified, the usual
asymptotics may not hold, in the sense that information accrual
may be minimal with increasing sample sizes. This subtle issue
is discussed and illustrated with data analyses and simulations
in Jansen et al. (2006) and the references therein. Practically, it
means that parameters distinguishing missing not at random
from missing at random under the posited model may be
identifiable from the observed data, but only barely so.
A third missing not at random model was fitted
where the model of missingness has the following form:
logit p ij=θ0+θ1 y ij+θ2 y ijS i+θ3y ijH i. This model allows
the missingness to depend on the unobserved HAM-D value,
while allowing for a different mechanism in each treatment
arm by including the HAM-D score by treatment interaction.
The priors are given in Table 4. The priors were chosen to be
flat and therefore uninformative. The parameters were varied
from extremely flat priors, to less flat priors in order to
investigate whether the models were sensitive to the choice
of prior. Many other models for nonrandommissingness could
be fitted, depending on the assumptions made regarding the
missing data mechanism.
The assumptions made by the models fitted were tested. The
assumption of linear regression was tested by plotting the
studentized residuals against the predicted means. This plot
showed no deviations from the assumption of linear regression.
The normality assumption was tested by looking at the normal
probability plot of the residuals. No deviation from normality
was present. Different variance covariance structures were fitted
and the most appropriate was chosen using Akaike Information
Criterion (AIC) and Bayesian Information Criterion (BIC).
All analyses were performed on the data collected from
baseline to week 8, using SAS version 9.3 software (SAS
Institute Inc, Cary, NC), with the exception of the Bayesian
analyses, which were performed using OPENBUGS version
3.2.2. All assumptions of linear regression were satisfied.
Results
The trial enrolled 428 participants in the run-in phase and 340
were randomized to the tree treatment arms. The demographics
of the sample and the CONSORT diagram is described else-
where (Hypericum Depression Trial Study Group 2002). The
mean pooled baseline HAM-D score was 22.8 (SD=2.7). A
large number of participants was lost to follow-up before week
8; 28.8 % in the sertraline arm, 27.4 % in the hypericum arm,
and 27.6 % in the placebo arm. At the end of week 8, the
percentage participants who dropped out were similar across
the three arms; however, participants discontinued sooner in the
active arms, especially in the sertraline arm. The extent of and
reason for missing data at each visit is given in Table 1.
A central question is whether the missing data are missing
completely at random, missing at random, or missing not at
random. Although the data cannot exclude missing not at
random, it can hold some evidence of informative
missingness. Figures 1 and 2 compare the HAM-D score of
participants who dropped out at the next visit to those of
participants who did not drop out at the next visit.
Participants who dropped out are different from those who
did not drop out. Prior to week 4, dropouts had lower HAM-D
scores than those who did not drop out. Fromweek 4 onwards,
dropouts had higher HAM-D scores than participants who did
not drop out; thus, dropout depends at least on observed
HAM-D score. Among demographic and baseline variables,
duration of depression and age were significantly associated
with dropout in a logistic regression.
The fact that some withdrawals were due to insufficient
response suggested that HAM-D score should not be analyzed
without taking missing data into account. In addition, the fact
that participants started dropping out sooner in the sertraline
arm might reflect that tolerability issues were related to drop-
out, casting further doubt on the suitability of a missing at
random model. Ignoring participants who drop out due to
insufficient response or tolerability issues will introduce an
important bias in the complete case analysis. In this context,
the missing at random based model expresses the assumption
that a participant's observed history is deemed adequate to
derive his or her probability of dropping out. Here, history is
to be understood as the combination of the patient's outcomes
from the beginning of the study up to but not including the
current one, and the covariate information, collected at
baseline and during follow-up, up to the current time. Up
to week 8, a missing completely at random analysis is not
appropriate; a missing at random analysis might be appro-
priate, but missing not at random cannot be ruled out.
Assumptions about the missing data, other than missing at
random should be considered.
In the original paper, the mean HAM-D scores using
available case analysis were given in a figure. According
to this figure, the sertraline arm showed the largest im-
provement over time. It also included a random coefficient
regression analysis on the longitudinal HAM-D total
scores. This analysis detected a downward linear trend with
week (p value<0.001). Linear trends with week did not
Psychopharmacology (2014) 231:1987–1999 1991
differ significantly by treatment (hypericum versus placebo,
p value=0.59; sertraline versus placebo, p value=0.18). If
this analysis was done using all data points while fitting a
mixed model using maximum likelihood estimates, this anal-
ysis is consistent with missing at random assumptions
(Hypericum Depression Trial Study Group 2002). From the
original paper, model estimates for the mean change from
baseline to week 8 in HAM-D score were calculated for each
of the treatment arms (Table 2). The conclusion was that
neither hypericum nor sertraline was superior to placebo.
The authors highlighted the high level of improvement in
the placebo arms often seen in depression trials (Hypericum
Depression Trial Study Group 2002).
We compared the change from baseline to week 8 using
multiple imputation. The change was slightly larger in all arms
using multiple imputation, but the p values were similar to the
previous analysis. We conclude that there is no difference
between either of the treatment arms and the placebo arm
(Table 2).
The results for the change from baseline to week 8 using
multiple imputation and a mixed model are presented in
Tables 2 and 3, respectively. Multiple imputation and
likelihood-based methods make similar assumptions about the
missing data, namely that it is missing at random. The conclu-
sions are expected to be similar. Neither analysis found either of
the treatments to be different from placebo. Analyzing the data
Table 1 Number of participants attending each visit
Sertraline N=111 Hypericum N =113 Placebo N=116
Number with Hamilton depression score at N Number missing (%) N Number missing (%) N Number missing (%)
Baseline 111 – 113 – 116 –
Week 1 101 10 (9.0) 101 12 (10.6) 111 5 (4.3)
Week 2 90 21 (18.9) 102 11 (9.7) 107 9 (7.8)
Week 3 90 21 (18.9) 100 13 (11.5) 94 22 (19.0)
Week 4 89 22 (19.8) 97 16 (14.2) 99 17 (14.7)
Week 6 82 29 (25.1) 91 22 (19.5) 93 23 (19.8)
Week 7 79 32 (28.8) 82 31 (27.4) 84 32 (27.6)
Week 8 79 32 (28.8) 82 31 (27.4) 84 32 (27.6)
Enter continuation phase 49 38 42
Reasons not completing acute phase (week 8) N=32 N =31 N =32
Loss to follow-up 10 31.3 % 8 25.8 % 7 21.9 %
Insufficient response 7 21.9 % 6 19.4 % 11 34.4 %
Withdrew consent 8 25.0 % 7 22.6 % 8 25.0 %
Adverse event 5 15.6 % 2 6.5 % 3 9.4 %
Protocol violation 2 6.3 % 8 25.8 % 3 9.4 %
Fig. 1 Sample mean of Hamilton depression score at each week for all
treatment groups combined. The triangles are themeans for participants who
did not drop out before the subsequent measurement. The circles are the
means for participants who dropped out before the subsequent measurement
Fig. 2 Sample mean of Hamilton depression score at each week by
treatment group. Not drop out gives the means for participants who did
not drop out before the subsequent measurement. Drop out gives the means
for participants who dropped out before the subsequent measurement
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using a likelihood-basedmodel found the only significant effect
to be week, indicating that depression decreased over time
(Table 3).
The choice of a vague prior did not change the results
appreciably in the Bayesian missing at random analysis
(Table 4). The results were similar to the maximum likelihood
model, with one notable exception. Under the maximum
likelihood model, none of the treatment effects was signifi-
cant; however, under this model, the interaction between the
sertraline arm and week was significant, indicating that the
decrease in HAM-D score over time was larger in the sertra-
line arm than in the placebo arm, regardless of the choice of
prior.
Under the missing not at random assumption, we did
several Bayesian analyses as a sensitivity analysis. The results
under the first missing not at random Bayes model did not
differ appreciably from the results under the missing at ran-
dom Bayes model. Under prior sets 1 and 2, the results were
almost similar. The posterior means were slightly different
under the less flat and therefore more nonrandom priors used
in prior set 3. Prior set 3 was the most informative prior used in
that provided the strongest prior belief against the missing not
at random assumption. However, the conclusions were the
same regardless of prior set used. There was a significant
interaction between sertraline and week, meaning that the
sertraline arm had a larger decrease in HAM-D score than
the placebo arm over time. Under missing not at random
model 2, the posterior means for the β-coefficients were
similar to the posterior means under missing not at random
model 1, with the exception of sertraline and hypericum under
prior sets 2 and 3. This model was more sensitive to the choice
of prior than model 1. The conclusion drawn is the same,
except under prior set 2, where the interaction between sertra-
line and week just did not meet statistical significance.
These results need to be interpreted with caution. First, as
was discussed in Jansen et al. (2006), a test for missing not at
random versus missing at random is valid only under the
untestable assumption that the missing not at random alterna-
tive is correctly specified. Secondly, even then, this test has
been shown not to have the usual power behavior, simply
because there is information missing. Evidently, this problem
cannot be avoided, hence the need for sensitivity analysis.
Missing not at random model 1 is sometimes called “pro-
tective” (Michiels andMolenberghs 1997) and is specific in the
sense that dropout can depend on the current, possibly unob-
served, measurement, but not on the previous one. Intuitively, it
is a mirror image of a commonly used missing at random
model, where missingness depends on the previous but not
current value. Assuming that previous and current values are
often relatively similar, these models are often not too different
from each other, establishing that they retain some of the
stability of missing at random models. Model 2, on the other
hand, allows missingness to depend on previous and current
measurements, and therefore also on the increment between
them. This is a profound departure frommissing at random, and
about the increment there is often not a lot of information in the
data, because it is by definition unknown for someone dropping
out, at the time of dropout (Jansen et al. 2006). As a result, it is
expected that the model is more sensitive to unverifiable as-
sumptions or choices made, such as prior specification.
Discussion
The conclusion drawn in the original paper was that there was
no difference between either the hypericum arm and placebo or
the sertraline arm and placebo. This was taken to mean that the
study results were inconclusive. Although it showed that
hypericum was no better than placebo, it also did not find the
expected difference between sertraline and placebo (Hypericum
Depression Trial Study Group 2002). The same was found
when the continuation data was analyzed, and the placebo
effect was again noted and discussed (Sarris et al. 2012). The
last observation carried forward analysis used previously was
not a plausible assumption in this instance because of the week
effect found. It penalized the armwith higher or earlier dropout;
in this instance, the sertraline arm. This explains why the
original analyses had inconclusive results. We reanalyzed the
Table 3 Results fitting a mixed model
With multiple imputation Without multiple imputation
Estimate Standard error 95 % CI p value Estimate Standard error 95 % CI p value
Intercept 22.70 0.25 22.22; 23.19 23.17 0.25 22.68; 23.66
Week −1.15 0.09 −1.33; −0.96 <0.001 −1.23 0.08 −1.40;−1.07 <0.001
Sertraline versus placebo 0.09 0.35 −0.60; 0.78 0.79 −0.08 0.36 −0.75; 0.66 0.81
Hypericum versus placebo 0.42 0.35 −0.26; 1.10 0.23 0.27 0.35 −0.43; 0.97 0.45
Week by sertraline −0.23 0.13 −0.48; 0.02 0.08 −0.19 0.12 −0.43; 0.05 0.12
Week by hypericum 0.01 0.13 −0.24; 0.25 0.95 0.07 0.12 −0.16; 0.31 0.55
CI Confidence interval
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data using methods that are appropriate with missing data. We
fitted various models using different assumptions about the
missing data and various analysis methods. Under this extended
sensitivity analysis, we draw a different conclusion.
Themissing data in this study was not missing completely at
random.We did a range of sensitivity analyses under missing at
random and missing not at random assumptions. Some of our
conclusions are similar to the original analysis, but both the
missing at random and missing not at random analyses using
Bayesian methods lead to the conclusion that sertraline is
significantly better than placebo in reducing depression
symptoms over 8 weeks. No difference was found between
hypericum and placebo in any of the analyses. Our sensitivity
analysis penalized the sertraline group less than the previous
analysis and therefore showed that there was a difference
between sertraline and placebo. The change from baseline to
week 8 for sertraline was −10.64 (95 % CI −11.52, −9.77) and
placebo was −9.36 (95 % CI −10.2, −8.52) according to the
missing at random Bayesian model with prior set 1.
While there are strong similarities between likelihood and
Bayesian missing at random analyses, a key difference is the
absence versus presence of a prior specification. The impact of
Table 5 Summary of all the statistical methods used; their key features and main assumptions
Method Key features Assumptions
Missing at random
Likelihood-based approaches Parametric model; Draw inference about a
parameter, θ , in a model f (y|θ) for the
response data that is not fully observed. Model
with fixed and random effects, including treatment,
week and the interaction between treatment
and week, adjusted for repeated measures
Missing at random Missing data mechanism
is ignorable. No need to specify a model
that relates the missing data process to the
observed data.
Multiple imputation Produce several different imputed data sets. The
imputed values are random draws from the posterior
predictive distribution of the missing data, given the
observed data. Apply likelihood-based estimation
methods to each data set. Parameter estimates are
averaged across the several analyses. Standard errors
are calculated using Rubin's (1987) formula that
combines variability within and between data sets. The
imputation model included: HAM-D, age, sex, race,
duration of depression, BDI, CGI-S, CGI-I, and
GAF scale at baseline.
Missing at random Data are from a multivariate
normal distribution. Missing values can occur




Bayesian model: Yij~Normal(μ ij,σ
2) μ ij=β0+β1t ij+
β2Si+β3Hi+(β4Si+β5Hi)t ij The Bayesian inference
is done by specifying a model and prior distributions
for the parameters of the model, and then updating the
prior information on the parameters using the model
specified and the data observed to obtain the posterior
distribution of the parameters. Vague priors were
specified for the unknown parameters and are given
in Table 4.
Missing at random Parameters are treated as
random variables. Probability statements are
made about the model parameters and not
about the data
Missing not at random
Bayesian missing not at
random model 1
Bayesian model: Yij~Normal(μ ij,σ
2) μ ij=β0+β1t ij+
β2Si+β3Hi+(β4Si+β5Hi)t ij Plus a model of missingness:
logit pi,w=θ0+θ1yi,w−1+θ2(yi,w−yi,w−1). Key features
as described for previous missing at random model. Vague
priors were specified for the unknown parameters and
are given in Table 4.
Missing not at random Parameters are treated
as random variables. Probability statements
are made about the model parameters and
not about the data
Bayesian missing not at
random model 2
Bayesian model: Yij~Normal(μ ij,σ
2) μ ij=β0+β1t ij+β2Si+
β3Hi+(β4Si+β5Hi)t ij Plus a model of missingness: logit
pi,w=θ0+θ1yi,w−1+θ2(yi,w−yi,w−1). Key features as
described for previous missing not at random model. Vague
priors were specified for the unknown parameters and
are given in Table 4.
Missing not at random Parasmeters are treated
as random variables. Probability statements
are made about the model parameters and
not about the data
Bayesian missing not at
random model 3
Bayesian model: Yij~Normal(μ ij,σ
2) μ ij=β0+β1t ij+β2Si+
β3Hi+(β4Si+β5Hi)t ij Plus a model of missingness: logit
pij=θ0+θ1yij+θ2yijSi+θ3yijHi. Key features as described
for previous missing not at random model. Vague priors were
specified for the unknown parameters and are given in Table 4.
Missing not at random. This model allows the
missingness to depend on the unobserved
HAM-D value, while allowing for a different
mechanism in each treatment arm by including
the HAM-D score by treatment interaction.
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the prior is perhaps one of the most studied topics in Bayesian
analyses, already in the context of no missing data. It suggests
that the missing at random based Bayesian analysis can be
more sensitive to assumptions made than the missing at ran-
dom based likelihood or multiple imputation analyses, simply
because more assumptions have to be made.
This implies that the conclusion reached 10 years ago could
be amended to state that hypericum does not seem to provide
any benefit over placebo, in a trial where it could not be ruled
out that the active comparator could provide a slight benefit
over placebo. This illustrates the point that not taking account
of missing data in the analysis could introduce bias and lead to
incorrect results.
Adjusting the analysis to takemissing data into account does
not imply changing the proposed estimate of effectiveness. The
measure of effectiveness reported in the original paper was
change from baseline to week 8. We analyzed the same esti-
mate under missing at random assumptions using either multi-
ple imputation or likelihood-based methods (Table 5). In gen-
eral, multiple imputation allows any measure of effectiveness,
since the analysis of choice is done in the second step.
The trial design only continued participants with a full
response at week 8 to the continuation phase. Thus only a
fraction of the participants (37.9 %) will have data in the
continuation phase. Because of nonrandom exclusion of par-
ticipants, the comparability of the three treatment arms after
week 8 is not equivalent to a randomized trial. At best, this
provides an observational study about the longer term effects
of the drugs. Any efficacy analysis in this continuation phase
should be interpreted with caution. This design should be
discouraged, unless the objective is to estimate sustained
response in those who responded initially. Because of the
small number of participants in the continuation phase, the
correct handling of missing data in this phase is important.
The missing data mechanism is probably missing at random
by design, since missingness can be predicted by the response
to treatment at week 8. Missing not at random missing data
cannot be excluded either, since additional mechanisms could
also contribute to the missing data in this phase. It becomes
evenmore important to analyze the data fromweek 8 onwards
using appropriate methods for missing data.
The analysis was done with standard statistical software,
using resources that should be available to most researchers.
The unavailability of software should no longer be a reason not
to do the proper principled analyses in the presence of missing
data.
Conclusion
There is no difference between hypericum and placebo, regard-
less of the assumption about the missing data process, but there
is a significant difference between sertraline and placebo with
some of the analyses assuming a missing at random missing
data process and when a missing not at random missing data
process is assumed. The assumptions about the missing data
process could influence the results, as is shown by this example.
This reanalysis of the original data, using proper missing data
processes, changes the original conclusion of the trial. The
original conclusion was that the trial was inconclusive, since
the active control armwas not superior to placebo. The findings
using these methods conclude that the sertraline arm could be
superior to placebo under certain assumptions about the miss-
ing data process. This means that the original trial was not
inconclusive, but found that hypericum was not superior to
placebo. It is important to conduct an analysis that takes account
of missing data using valid statistically principled methods.
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